bewar histori icd underweight
break trial argu increas penetr tremend growth market
even growth y/i seen growth market
long term much engag bid war guidant
forward today icd matur market anchor growth
ew trade nearli street ep believ stock overvalu
manag dampen tavr expect despit come well ahead
expect note expect tavr procedur return double-digit
growth view impli single-digit growth outlook like
convey decemb analyst day tavr sale mean
compani overal underli growth go slow single-digit well
meaning transcathet mitral tricuspid tmtt sale opportun
second chapter ew growth still year away manag over-
estim tmtt sale past two year expect tmtt sale doubl next
year estim view meaning opportun
us edward comment us approv date put asid patent
clinicaltri gov year-end put fda approv edward
expect start us sapien trial year us approv like year
put togeth street longer term outlook look high tavr growth
rate slow get harder maintain therapi penetr rate
meaning contribut tmtt opportun us launch still mani year
away ew sale growth like slow price-to-earnings like compress
still concern subacut thrombosi weekend aha meet
galileo/galileo trial present studi look xarelto
prevent subacut thrombosi halt earli due higher bleed rate
rais pt due higher ep prior
unchang price-to-earnings still current valu henc underweight rate
ew quarterli annual ep usd
consensu number bloomberg receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
rais usd
return equiti ttm
link barclay live interact chart
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
underweight believ sale growth like
slow edward face competit transcathet
aortic valv tavr expect limit leverag
edward invest transcathet mitral valv
tmvr/r opportun sale ep estim
street tmvr/r repres potenti
second act still risk like
upsid case may driven better-than-
expect tavr sale greater leverag
stronger uptak tmvr europ faster-
than-expect time tmvr/r product
downsid case may driven delay
inabl commerci tmvr/r technolog
slowdown tavr sale due market slowdown
and/or competit pressur fx rate
greater expens support tmvr/r
sale ep came well street/our estim driven
underli growth tavr sale structur heart sale critic
sale rel line street/our estim tmtt sale
expect overal sale reflect
underli growth edward expect full year sale top end previou
rang ep guidanc rais
net/net view quarter impress howev given valuat view
growth outlook coupl
linger concern sub-clin
thrombosis/valv durabl maintain underweight rate
addit detail quarter
million except per share data chang sale constant currenc underli basi unless otherwis note
tavr sale well street estim
estim edward abl overcom tradit
season strength low-risk indic sapien sapien ultra
surgic structur heart underli sale surpris given
strength tavr manag highlight growth due premium product
adjust ep street estim driven
notabl tavr sale perform ew rais full-year ep guidanc
manag comment earli forecast process
model return low-double-digit tavr procedur growth next year
tmtt sale street estim
manag expect full year tmtt sale versu
cite disciplin introduct premium price strategi ytd sale
sale billion underli basi underli growth
divis tavr structur heart critic tmtt
sale
gross margin y/i driven favor fx impact product
mix partial off-set spend eu mdr manufactur varianc
sg sale y/i decreas larg function
higher sale despit invest european mitral field personnel relat expens
 sale bp y/i due invest transcathet
oper margin y/i
adjust tax rate y/i includ benefit
stock-bas compens well benefit tax reform switzerland
adjust ep street estim
edward expect sale versu street pre-releas ep versu street pre-
edward expect total sale around top end previou rang edward expect tavr sale
around top end previou rang underli sale growth nearli prior compani expect tmtt
sale prior structur heart sale chang critic sale around top end
previou rang chang gross margin expect in-lin ytd rate versu prior guidanc
sg still expect around year still expect tax rate expect
bottom end rang reflect increas benefit stock base compens net/net edward rais full year
ep guidanc rang
actual million salesrptdunderlyingtranscathet aortic mitral tricuspid heart street divis estim streetaccount els refinitivyoy barclay edward lifesci corp
addit takeaway earn call pleas see note
click titl link
kstew call note focus management attempt rein tavr expect
model avail barclay live via link
kristen stewart cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli
relat specif recommend view express research report
